首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Xcl1 |
| Uniprot No | P47992 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-114aa |
| 氨基酸序列 | GSEVSDKRTC VSLTTQRLPV SRIKTYTITE GSLRAVIFIT KRGLKVCADP QATWVRDVVR SMDRKSNTRN NMIQTKPTGT QQSTNTAVTL TG |
| 预测分子量 | 10.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **XCL1重组蛋白** 的3篇代表性文献摘要(示例格式，仅供参考)：
---
1. **文献名称**：*"Recombinant XCL1 Expression in E. coli: Purification and Functional Characterization"*
**作者**：Smith A, et al.
**摘要**：本研究报道了在大肠杆菌系统中高效表达并纯化重组XCL1蛋白的优化方法，通过体外趋化实验证实其能有效诱导T淋巴细胞迁移，为后续免疫研究提供工具。
2. **文献名称**：*"XCL1 Enhances Antitumor Immunity by Recruiting CD8+ T Cells via XCR1 Signaling"*
**作者**：Zhang Y, et al.
**摘要**：利用重组XCL1蛋白在小鼠模型中验证其通过结合XCR1受体激活CD8+ T细胞，显著抑制肿瘤生长，提示其在癌症免疫治疗中的潜在应用。
3. **文献名称**：*"Structural Insights into XCL1 and Its Receptor Interaction by Cryo-EM"*
**作者**：Johnson R, et al.
**摘要**：通过冷冻电镜解析重组XCL1与其受体XCR1的复合物三维结构，揭示了趋化因子特异性识别的分子机制，为设计靶向药物提供结构基础。
---
*注：以上为模拟示例，实际文献需通过PubMed、Web of Science等数据库检索关键词(如"recombinant XCL1"、"XCL1 protein engineering")。*
XCL1 (chemokine (C motif) ligand 1), also known as lymphotactin, is a unique member of the chemokine family that plays a critical role in immune regulation. Unlike most chemokines classified into CXC or CC subfamilies, XCL1 belongs to the XC subfamily due to its singular cysteine motif (C). It is primarily secreted by activated CD8+ T cells, natural killer (NK) cells, and thymic dendritic cells, acting as a chemoattractant for immune cells expressing its receptor XCR1. which is predominantly found on cross-presenting dendritic cells (cDC1). This XCL1-XCR1 axis is crucial for coordinating adaptive immune responses, particularly in antiviral defense and antitumor immunity.
Recombinant XCL1 protein is engineered through genetic modification, typically using bacterial (e.g., E. coli) or mammalian expression systems. The protein’s native structure contains 114 amino acids, including a conserved chemokine domain and a C-terminal extension that influences receptor binding specificity. However, native XCL1 exhibits structural instability due to a dynamic equilibrium between monomeric and dimeric forms under physiological conditions. To address this, modified variants like "Ltn-II" (a stabilized mutant) have been developed for experimental and therapeutic applications.
Research applications of recombinant XCL1 include studying immune cell migration, dendritic cell-mediated antigen presentation, and tumor microenvironment modulation. Its therapeutic potential is being explored in cancer immunotherapy, particularly for enhancing dendritic cell recruitment to tumors. Challenges remain in maintaining its structural integrity and receptor specificity in vivo, prompting ongoing protein engineering efforts. Recent studies also highlight its role in vaccine adjuvant design and autoimmune disease regulation, underscoring its dual functionality as both a chemoattractant and an immune modulator.
×
